Real‐world use of maintenance bacillus Calmette‐Guérin therapy in patients with non‐muscle‐invasive bladder cancer in Japan: ASUKA study

Documenti analoghi

• Intravesical gemcitabine and docetaxel vs. re‐induction Bacillus Calmette Guerin as first‐line salvage therapy for non‐muscle invasive bladder cancer
  di: Kylie Yen‐Yi Lim, et al.
  Pubblicazione: (2025)
• Novel neoadjuvant therapies for muscle‐invasive bladder cancer: Systematic review and meta‐analysis
  di: Shugo Yajima, et al.
  Pubblicazione: (2025)
• Time to abandon routine urine analysis prior to Bacillus Calmette–Guérin administration in asymptomatic patients
  di: Antti Nummi, et al.
  Pubblicazione: (2025)
• Quantification of perineural invasion on prostate biopsy improves risk stratification in biopsy Grade Group 2–3 cancer
  di: Yuki Teramoto, et al.
  Pubblicazione: (2026)
• Perioperative chemotherapy use and related outcomes in muscle‐invasive bladder cancer in Australia
  di: Alison Hiong, et al.
  Pubblicazione: (2025)